Literature DB >> 11309333

Semenogelins are ectopically expressed in small cell lung carcinoma.

R G Rodrigues1, A Panizo-Santos, J A Cashel, H C Krutzsch, M J Merino, D D Roberts.   

Abstract

Two proteins recovered from cell surface adhesion complexes in a small cell lung carcinoma (SCLC) cell line were identified as fragments of the seminal plasma proteins semenogelin I and semenogelin II. Association of both proteins with the adhesion complexes was induced by epidermal growth factor. Expression of semenogelins was previously thought to be highly specific to seminal vesicles, but Western blot analysis demonstrated that semenogelin II is widely expressed in SCLC cell lines and occasionally in other malignant cell lines. Although semenogelin expression is normally restricted to males, two SCLC cell lines from female patients were also positive for semenogelin II expression. Immunohistochemical analysis demonstrated diffuse expression of semenogelins in 12 of 13 SCLC tumors and focal expression in a minority of lung squamous and adenocarcinomas. Semenogelins were secreted into the medium by cultured SCLC cells, which suggested that these proteins may be useful markers for detecting residual tumor burden or recurrence of SCLC after treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309333

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

Authors:  Yana Zhang; Zhiqing Wang; Jian Zhang; Benjamin Farmer; Seah H Lim
Journal:  Leuk Res       Date:  2008-05-12       Impact factor: 3.156

2.  Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis.

Authors:  Shengli Zhang; Jianzheng Fang; Xiangxiang Zhang; Chao Qin; Shifeng Su; Yunfei Deng; Zhen Song; Yi Zhang; Hainan Wang; Changjun Yin; Zengjun Wang
Journal:  Tumour Biol       Date:  2014-06-11

3.  Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.

Authors:  Amosy E M'Koma; David L Blum; Jeremy L Norris; Tatsuki Koyama; Dean Billheimer; Saundra Motley; Mayshan Ghiassi; Nika Ferdowsi; Indrani Bhowmick; Sam S Chang; Jay H Fowke; Richard M Caprioli; Neil A Bhowmick
Journal:  Biochem Biophys Res Commun       Date:  2006-12-22       Impact factor: 3.575

4.  Semenogelins in the human retina: Differences in distribution and content between AMD and normal donor tissues.

Authors:  Vera L Bonilha; Mary E Rayborn; Karen G Shadrach; Yong Li; Ake Lundwall; Johan Malm; Joe G Hollyfield
Journal:  Exp Eye Res       Date:  2007-10-25       Impact factor: 3.467

Review 5.  Emerging roles of cancer-testis antigenes, semenogelin 1 and 2, in neoplastic cells.

Authors:  Oleg Shuvalov; Alyona Kizenko; Alexey Petukhov; Olga Fedorova; Alexandra Daks; Nikolai Barlev
Journal:  Cell Death Discov       Date:  2021-05-08

6.  SEMG1/2 augment energy metabolism of tumor cells.

Authors:  Oleg Shuvalov; Alyona Kizenko; Alexey Petukhov; Olga Fedorova; Alexandra Daks; Andrew Bottrill; Anastasiya V Snezhkina; Anna V Kudryavtseva; Nikolai Barlev
Journal:  Cell Death Dis       Date:  2020-12-11       Impact factor: 8.469

7.  Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.

Authors:  Prashant Kumar; Sayantani Nandi; Tuan Zea Tan; Siok Ghee Ler; Kee Seng Chia; Wei-Yen Lim; Zentia Bütow; Dimitrios Vordos; Alexandre De la Taille; Muthafar Al-Haddawi; Manfred Raida; Burkhard Beyer; Estelle Ricci; Marc Colombel; Tsung Wen Chong; Edmund Chiong; Ross Soo; Mi Kyoung Park; Hong Koo Ha; Jayantha Gunaratne; Jean Paul Thiery
Journal:  Oncotarget       Date:  2015-05-30

8.  Proteomic changes of alveolar lining fluid in illnesses associated with exposure to inhaled non-infectious microbial particles.

Authors:  Laura Teirilä; Kirsi Karvala; Niina Ahonen; Henrik Riska; Anne Pietinalho; Päivi Tuominen; Päivi Piirilä; Anne Puustinen; Henrik Wolff
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.